The first total synthesis of potent antitumoral (±)-mafaicheenamine A, unnatural 6-fluoromafaicheenamine A and expedient synthesis of clausine E

Yasir Abbasa, Muhammad Manshaab and Nisar Ullah*a
aChemistry Department, King Fahd University of Petroleum and Minerals, Dhahran, Saudi Arabia. E-mail: nullah@kfupm.edu.sa; Fax: +966 13 860 4277; Tel: +966 13 8607527
bCentre of Research Excellence in Nanotechnology, King Fahd University of Petroleum and Minerals, Dhahran, Saudi Arabia

Received 3rd February 2016 , Accepted 2nd March 2016

First published on 3rd March 2016


Abstract

The first total synthesis of potent antitumoral mafaicheenamine A (1) and its unnatural analogue, 6-fluoromafaicheenamine A (2) have been accomplished. An expedient synthesis of clausine E, a key intermediate in the course of synthesis of 1 and 2, was achieved in three steps from commercially available methyl 4-amino-3-(benzyloxy)benzoate (10) by copper-catalyzed N-arylation with aryllead triacetate, followed by cyclodehydrogenation of the resultant diarylamine under palladium(II) acetate catalysis. Moreover, palladium-catalyzed O-prenylation of clausine E and subsequent o-Claisen rearrangement under microwave irradiation rendered the advanced intermediate, C-prenylated phenol, which was eventually subjected to oxidative cyclization to construct the dihydroisocoumarin unit, leading to the synthesis of 1 and 2 in 12% and 15% overall yield, respectively, from 10.


Introduction

Cancer is one of the most leading causes of mortality. Despite of enormous efforts devoted to its prevention and treatment, it remains the second leading cause of death. As such, the discovery and development of anticancer agents has attracted a great deal of attention from several pharmaceutical companies as well as non-profit organizations.1 A recent study has revealed that since 1940s to date 48.6% approved anticancer agents were either natural products or directly derived there from. The study concluded that natural products as sources of novel structures are indispensable in anticancer lead-finding research.2

Naturally occurring carbazole alkaloids are known to exhibit numerous pharmacological activities including anti-bacterial,3 anti-malarial,4 anti-tuberculosis4 and anti-HIV.5 In addition, they have shown potent cytotoxic activity against several cancer cell lines such as prostate cancer,6 breast cancer,7 oral cavity cancer and small-cell lung cancer8,7b and human leukemia.9 Owing to the great utility of carbazoles, considerable efforts have been devoted to their isolation from natural sources10 as well as on the development of methods for their synthesis.11

In an effort towards to discover new bioactive compounds, phytochemical investigation of twigs of Clausena lansium has led the isolation and characterization of a new carbazole alkaloid, mafaicheenamine A (1) (Fig. 1).12 Compound 1 was evaluated for its antitumor activity against three human cancer cell lines namely: breast cancer (MCF7), oral cavity cancer (KB), and small lung cancer (NCI-H187). While exhibiting moderate activity against KB (1C50 = 7.68 μg mL−1) and NCI-H187 (1C50 = 13.27 μg mL−1), compound 1 showed potent activity against MCF7 (1C50 = 2.96 μg mL−1).


image file: c6ra03242g-f1.tif
Fig. 1 Chemical structures of mafaicheenamine A (1) and 6-fluoromafaicheenamine A (2).

Substitution of aromatic and heteroaromatic rings with fluorine substituent is a common practice in drug discovery. The incorporation of fluorine into a molecule can improve drug potency,13 target selectivity14 and also can address issues associated with drug metabolism.15 In a previous study, the effect of aromatic fluorine substitution in a series of thrombin inhibitors was investigated. The study revealed that incorporation of fluorine at C-4 of phenyl ring significantly enhanced the activity compared to when it was introduced at other positions of the phenyl ring. The high potency of 4-fluorophenyl derivative was rationalized due to the dipolar C–F⋯H–Cα and C–F⋯C[double bond, length as m-dash]O interactions between the 4-fluorophenyl ring and the enzyme's active site.16 In our continuing interest in the synthesis of bioactive natural products,17 we now wish to disclose the first total synthesis of 1 and its unnatural analogue, 6-fluoromafaicheenamine A 2 (Fig. 1). An expedient synthesis of clausine E, a key intermediate in the course of synthesis of 1 and 2, was also accomplished and describe herein.

Results and discussion

The synthesis of compound 1 was envisioned from intermediate 9 which was to be transformed to 1 by the operations of olefin metathesis followed by oxidative cyclization. To this end, ester 3 was reacted with allyl bromide in DMF, using K2CO3 as a base, to produce the known ester 4.18 The Claisen rearrangement of 4 to the corresponding C-allyl phenol in ortho-dichlorobenzene, N,N-dimethylaniline or DMF either by conventional heating or under microwaves was very low yielding (32%), requiring prolonged heating and higher reaction temperature (>150 °C). In all attempts the reaction led to the recovery of either hydrolyzed acid (in case of N,N-dimethylaniline) or starting material (in case of ortho-dichlorobenzene and DMF). Consequently, the nitro group of 4 was reduced with iron powder in a mixture of ethanol, acetic acid and water promoted by ultrasonic irradiation, generating 5 in high yield (90%).19 The initial attempts of Claisen rearrangement of intermediate 5 in N,N-dimethylaniline under conventional heating or microwave irradiation were very sluggish, resulting the formation of only 10% of the desired product. However, with an optimized condition the reaction in DMF under microwave irradiation at 180 °C for 2 h gave the desired rearranged phenol 6 in high yield (85%). The chemoselective methylation on the phenolic OH of 6 with diazomethane in diethyl ether did not go to the completion even with the use excess of diazomethane; the desired 7 was formed in a low yield (15%) along with the recovery of 6. In the second attempt, methylation was realized by stirring the solution of 6 in DMF with 1.3 equivalent of K2CO3 for 0.5 h followed by the addition of 1.2 equivalent of iodomethane. The amount of K2CO3 and short reaction time (1.5 h) was critical to obtain the desired 7 in high yield (73%). The N-arylation of ester 7 with bromobenzene under Buchwald–Hartwig conditions (Pd(dba)2, BINAP) rendered the desired 8 in a very low yield (16%). The reaction become relatively cleaner when the combination of Pd(OAc)2 and JohnPhos were used as catalyst and ligand, respectively but column chromatography purifications turned out to be tedious and the desired 8 was obtained in 20% yield. Consequently, N-arylation of ester 7 was realized under Barton conditions,20 using phenylead triacetate and copper(II) acetate as a catalyst to furnish the desired 8 in good yield (66%). Cyclodehydrogenation of 8 in acetic acid or DMF with catalytic or stoichiometric amounts of palladium(II) acetate and copper(II) acetate using either thermal induction21 or microwave heating22 at elevated temperatures did not yield the desired 9, the decomposition of 8 was observed in all cases (Scheme 1).
image file: c6ra03242g-s1.tif
Scheme 1 Synthesis of intermediate 9.

Failure in cyclodehydrogenation of 8 led us revised our synthetic strategy as outlined in Scheme 2. N-Arylation of commercially available ester 10 with phenylead triacetate under Barton conditions furnished the desired 11 in good yield (67%). The key step of cyclodehydrogenation on 11 was performed in acetic acid at 100 °C, using palladium(II) acetate as a catalyst to furnish the desired 13 in good yield (60%). Removal of O-benzyl protection of 13 with catalytic hydrogenation produced 15 (clausine E) in 34% overall yield from 10. Despite the fact that six procedures for the synthesis of clausine E are known,23 our synthetic method provide an efficient access to the synthesis of clausine E in an overall high yielding reactions sequence from a commercially available starting material.24 Next, Pd-catalyzed allylation of 15 at room temperature proceeded to give, after filtration, 17 which in turn was subjected as is to Claisen rearrangement under the optimized condition in DMF, using microwave irradiation at 180 °C for 2 h to afford the desired C-prenylated phenol 19 in 82% yield (over two steps). The chemoselective methylation on the phenolic OH of 19 was realized with iodomethane in DMF followed by the hydrolysis of the ester function under basic condition produced the desired 23 in 57% overall yield from 19 (Scheme 2). With compound 23 in hand, we next moved towards the construction of the dihydroisocoumarin unit of 1.25 To this end, acid 23 was treated with m-CPBA in CH2Cl2 followed by work-up with saturated NaHCO3 readily generated the desired 1 in 78% yield (Scheme 2). All the spectral data of 1 matched with those of natural mafaicheenamine A.12


image file: c6ra03242g-s2.tif
Scheme 2 Synthesis of mafaicheenamine A (1) and 6-fluoromafaicheenamine A (2).

Keeping in view the aforementioned importance and utility of fluorine substituents in drug discovery, the usefulness of our synthetic approach was extended towards the synthesis of 6-fluoromafaicheenamine A (2), an unnatural analogue of 1. As depicted in Scheme 2, 6-fluoroclausine E (16) was synthesized from 10 by the reaction sequence of N-arylation with 4-fluorophenylead triacetate, palladium(II) acetate mediated cyclodehydrogenation and removal of benzyl protection with catalytic hydrogenation. Likewise intermediate 22 was originated from 16 by the operations of Pd-catalyzed allylation, Claisen rearrangement and O-methylation. Finally basic hydrolysis of ester function of 22 followed by oxidative cyclization furnished the desired 2 in 15% overall yield from 10 in eight steps (Scheme 2).

Experimental

General

Melting points were determined on a Büchi apparatus (Büchi Labortechnik AG, Switzerland) and are uncorrected. Elemental analysis was carried out on a Perkin Elmer Elemental Analyzer Series 11 Model 2400 (PerkinElmer Inc. USA). IR spectra were recorded on a Perkin Elmer 16F PC FTIR spectrophotometer (PerkinElmer Inc. USA). 1H and 13C NMR spectra were measured in CDCl3 and d6-DMSO using TMS as internal standard on a JEOL JNM-LA 500 MHz spectrometer (JEOL USA Inc.). Analytical TLC was carried out on silica gel 60 F254 plates (E. Merck); column chromatography was carried out on silica gel (200–400 mesh, E. Merck).
Synthesis of methyl 3-(allyloxy)-4-aminobenzoate (5). To a suspension of 4 (0.3 g, 1.3 mmol) in a mixture of glacial acetic acid (4 mL), ethanol (4 mL) and water (2 mL) was added reduced iron powder (0.37 g, 6.6 mmol). The resulting suspension was exposed to ultrasonic irradiation at 30 °C for 3 h and the mixture was filtered to remove the iron residue, which was washed with ethyl acetate (30 mL). The filtrate was added 2 M KOH (20 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic extracts were washed with brine (2 × 30 mL) and water (3 × 50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residue was resolved on silica column, eluting with hexanes[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate (80[thin space (1/6-em)]:[thin space (1/6-em)]20) to afford the title compound 5 as a bright yellow oil. Yield: 0.25 g, 90%; IR (neat): 3373, 3312, 3025, 2946, 1682, 1608, 1573, 1571, 1426, 1363, 1302, 1208, 1136, 1101 cm−1; 1H-NMR (500 MHz, CDCl3): δ 3.85 (s 3H, OCH3), 4.28 (br. s, 2H, NH2), 4.60 (d, J = 5.5 Hz, 2H, OCH2CH[double bond, length as m-dash]CH2), 5.30 (dd, J = 1.5, 10.3 Hz, 1H, OCH2CH[double bond, length as m-dash]CH2), 5.41 (dd, J = 1.5, 17.1 Hz, 1H, OCH2CH[double bond, length as m-dash]CH2), 6.07 (m, 1H, OCH2CH[double bond, length as m-dash]CH2), 6.67 (d, J = 8.2 Hz, 1H, H-5), 7.45 (d, J = 1.8 Hz, 1H, H-2), 7.54 (dd, J = 1.7, 8.2 Hz, 1H, H-6); 13C-NMR (125.7 MHz, CDCl3): δ 51.66 (OCH3), 69.23 (OCH2CH[double bond, length as m-dash]CH2), 112.59, 113.27, 117.86, 119.39, 124.21, 132.98, 141.32, 144.95, 167.22 (C[double bond, length as m-dash]O). Anal. calcd for C11H13NO3: C, 63.76; H, 6.32; N, 6.76%. Found: C, 63.72; H, 6.35; N, 6.71.
Synthesis of methyl 2-allyl-4-amino-3-hydroxybenzoate (6). In a microwave reaction vessel, through a solution of 5 (2 g, 9.7 mmol) in DMF (4 mL) was bubbled nitrogen for 1 min and vessel was then placed inside CEM Discover S-Class microwave synthesizer where it was exposed to microwaves at 180 °C (260 W) for 2 h. After completion of the reaction, the mixture was diluted with ethyl acetate (50 mL), washed with water (10 mL) and then washed with brine (5 × 10 mL), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. Column chromatography purifications of the yellow oily material, eluting with hexanes[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate (50[thin space (1/6-em)]:[thin space (1/6-em)]50) to obtain compound 6 as an off white solid. Yield: 1.7 g, 85%; m.p. 91–92 °C; IR (neat): 3408, 3313, 3002, 2947, 1693, 1601, 1493, 1441, 1277, 1191, 1100, 1015 cm−1; 1H-NMR (500 MHz, CDCl3): δ 3.82 (s, 3H, OCH3), 3.89 (d, J = 6.1 Hz, 2H, ArCH2CH[double bond, length as m-dash]CH2), 4.12 (br. s, 2H, NH2), 5.15–5.19 (m, 2H, OCH2CH[double bond, length as m-dash]CH2), 6.06 (m, 1H, OCH2CH[double bond, length as m-dash]CH2), 6.60 (d, J = 8.2 Hz, 1H, H-5), 7.50 (d, J = 8.2 Hz, 1H, H-6); 13C-NMR (125.7 MHz, CDCl3): δ 31.64 (ArCH2CH[double bond, length as m-dash]CH2), 51.57 (OCH3), 112.44, 116.13, 119.13, 125.49, 126.88, 136.45, 139.87, 142.00, 167.82 (C[double bond, length as m-dash]O). Anal. calcd for C11H13NO3: C, 63.76; H, 6.32; N, 6.76%. Found: C, 63.71; H, 6.34; N, 6.72.
Synthesis of methyl 2-allyl-4-amino-3-methoxybenzoate (7). In a solution of 6 (0.2 g, 0.97 mmol) in DMF (5 mL) was added K2CO3 (0.27 g, 1.93 mmol) and after being stirred for 30 minutes at room temperature, iodomethane (0.1 mL, 1.45 mmol) was added and the reaction mixture was further stirred for 1 h at room temperature. The mixture was diluted with water (30 mL) and then extracted with ethyl ether (2 × 15 mL). The combined organic layers was washed with water (10 mL) and brine (10 mL) and then dried over anhydrous Na2SO4 and evaporated under reduced pressure. Column chromatography of the light yellow oily material on silica gel eluting with petroleum ether[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate (90[thin space (1/6-em)]:[thin space (1/6-em)]10) gave the title compound 7 as a dark pink crystalline solid. Yield: 0.16 g, 76%; m.p. 89–90 °C; IR (neat): 3505, 3374, 3026, 2938, 1687, 1612, 1427, 1335, 1261, 1029 cm−1; 1H-NMR (500 MHz, CDCl3): δ 3.75 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.85 (d, J = 5.8 Hz, 2H, ArCH2CH[double bond, length as m-dash]CH2), 4.95–5.00 (m, 2H, ArCH2CH[double bond, length as m-dash]CH2), 6.05 (m, 1H, ArCH2CH[double bond, length as m-dash]CH2), 6.62 (d, J = 8.2 Hz, 1H, H-5), 7.64 (d, J = 8.2 Hz, 1H, H-6); 13C-NMR (125.7 MHz, CDCl3): δ 30.73 (ArCH2CH[double bond, length as m-dash]CH2), 51.47 (OCH3), 59.92 (OCH3), 112.59, 114.52, 119.49, 128.60, 135.98, 137.88, 143.89, 145.10, 167.42 (C[double bond, length as m-dash]O). Anal. calcd for C12H15NO3: C, 65.14; H, 6.83; N, 6.33%. Found: C, 65.10; H, 6.86; N, 6.28.
Synthesis of methyl 2-allyl-3-methoxy-4-(phenylamino)benzoate (8). To a solution of compound 7 (0.25 g, 1.12 mmol) in dry CH2Cl2 (15 mL) was added phenyllead triacetate (0.67 g, 1.47 mmol) followed by the addition of copper(II) acetate (0.04 g, 0.22 mmol) and the reaction was stirred at room temperature for 24 h until the reaction was completed (TLC analysis). The mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The residues was resolved on silica column, eluting with petroleum ether[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate (90[thin space (1/6-em)]:[thin space (1/6-em)]10) to get the title compound 8 as a pale yellow oil. Yield: 0.22 g, 66%; IR (neat): 3345, 3075, 2996, 1707, 1588, 1497, 1430, 1254, 1135, 1036 cm−1; 1H-NMR (500 MHz, CDCl3): δ 3.82 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.91 (d, J = 5.6 Hz, 2H, ArCH2CH[double bond, length as m-dash]CH2), 5.00–5.04 (m, 2H, ArCH2CH[double bond, length as m-dash]CH2), 6.07 (m, 1H, ArCH2CH[double bond, length as m-dash]CH2), 6.47 (br. s, 1H, NH), 7.09 (t, J = 5.6 Hz, 1H, Ar–H), 7.14 (d, J = 8.6 Hz, 1H, Ar–H), 7.22 (d, J = 8.4 Hz, 2H, Ar–H), 7.36 (m, 2H, Ar–H), 7.68 (d, J = 8.6 Hz, 1H, Ar–H); 13C-NMR (125.7 MHz, CDCl3): δ 30.90 (ArCH2CH[double bond, length as m-dash]CH2), 51.54 (OCH3), 60.65 (OCH3), 110.70, 114.67, 120.54, 120.64, 122.99, 126.04, 128.33, 128.39, 129.46, 135.72, 137.78, 140.71, 141.06, 146.21, 167.32 (C[double bond, length as m-dash]O). Anal. calcd for C18H19NO3: C, 72.71; H, 6.44; N, 4.71%. Found: C, 72.66; H, 6.49; N, 4.65.
Synthesis of methyl 3-(benzyloxy)-4-(phenylamino)benzoate (11). Following the same procedure adopted for the synthesis of 8, the reaction of compound 10 with phenyllead triacetate gave the title compound 11 as colorless crystalline solid. Yield: 0.26 g, 67%; m.p. 119–120 °C; IR (neat): 3399, 3024, 2946, 1692, 1587, 1515, 1493, 1440, 1418, 1380, 1347, 1268, 1221, 1101 cm−1; 1H-NMR (500 MHz, CDCl3): δ 3.90 (s, 3H, OCH3), 5.19 (s, 2H, OCH2Ph), 6.56 (br. s, 1H, NH), 7.08 (t, J = 7.3 Hz, 1H, Ar–H), 7.21–7.24 (m, 3H, Ar–H), 7.33–7.36 (m, 2H, Ar–H), 7.39 (m, 1H, Ar–H), 7.42–7.45 (m, 2H, Ar–H), 7.48 (d, J = 7.0 Hz, 1H, Ar–H), 7.62 (dd, J = 1.8, 8.2 Hz, 1H, Ar–H), 7.65 (d, J = 1.6 Hz, 1H, Ar–H); 13C-NMR (125.7 MHz, CDCl3): δ 51.81 (OCH3), 70.90 (OCH2Ph), 111.02, 112.46, 115.35, 119.85, 120.36, 121.14, 123.19, 124.19, 127.96, 128.37, 128.71, 129.41. 129.57, 136.34, 138.64, 140.53, 145.68, 156.03, 167.18 (C[double bond, length as m-dash]O). Anal. calcd for C21H19NO3: C, 75.66; H, 5.74; N, 4.20%. Found: C, 75.61; H, 5.78; N, 4.15.
Synthesis of methyl 3-(benzyloxy)-4-((4-fluorophenyl)amino)benzoate (12). Following the same procedure adopted for the synthesis of 8, the reaction of compound 10 with 4-fluorophenyllead triacetate gave the title compound 12 as a brown thick oil. Yield: 0.29 g, 70%; IR (neat): 3408, 3033, 2947, 1890, 1706, 1593, 1559, 1525, 1501, 1432, 1351, 1268, 1204, 1155, 1124, 1097 cm−1; 1H-NMR (500 MHz, CDCl3): δ 3.88 (s, 3H, OCH3), 5.17 (s, 2H, OCH2Ph), 6.44 (br. s, 1H, NH), 7.01–7.05 (m, 3H, Ar–H), 7.11–7.17 (m, 2H, Ar–H), 7.38–7.49 (m, 5H, Ar–H), 7.42 (t, J = 7.3 Hz, 2H), 7.62 (dd, J = 1.8, 8.2 Hz, 1H, Ar–H), 7.65 (d, J = 1.6 Hz, 1H, Ar–H); 13C-NMR (125.7 MHz, CDCl3): δ 51.79 (OCH3), 70.89 (OCH2Ph), 110.38, 112.38, 116.02, 116.21, 119.73, 123.86, 124.24, 128.03, 128.41, 128.72, 136.29, 136.40, 139.27, 145.41, 159.19 (d, J = 243.0 Hz, C-6), 167.11 (C[double bond, length as m-dash]O). Anal. calcd for C21H18FNO3: C, 71.78; H, 5.16; N, 3.99%. Found: C, 71.73; H, 5.19; N, 3.93.
Synthesis of methyl 1-(benzyloxy)-9H-carbazole-3-carboxylate (13). Under nitrogen atmosphere, to a solution of 8 (0.95 g, 2.85 mmol) in glacial acetic acid (60 mL) was added palladium(II) acetate (1.3 g, 5.7 mmol) and the mixture was heated at 100 °C for 24 h. The solvent was removed under reduced pressure and the residue was purified by flash chromatography on silica gel, eluting with petroleum ether[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate (80[thin space (1/6-em)]:[thin space (1/6-em)]20) to afford 13 as a colorless crystalline solid. Yield: 0.5 g, 55%; m.p. 149–150 °C; IR (neat): 3358, 3032, 2946, 1678, 1629, 1583, 1495, 1406, 1344, 1309, 1230, 1149, 1092 cm−1; 1H-NMR (500 MHz, CDCl3): δ 3.99 (s, 3H, OCH3), 5.31 (s, 2H, OCH2Ph), 7.27 (m, 1H, Ar–H), 7.39 (d, J = 7.3 Hz, 1H, Ar–H), 7.42–7.47 (m, 4H, Ar–H), 7.53 (d, J = 7.3 Hz, 2H, Ar–H), 7.72 (d, J = 1.6 Hz, 1H, Ar–H), 8.11 (d, J = 7.9 Hz, 1H, Ar–H), 8.51 (d, J = 1.6 Hz, 1H, Ar–H), 8.53 (br. s, 1H, NH); 13C-NMR (125.7 MHz, CDCl3): δ 52.06 (OCH3), 70.71 (OCH2Ph), 107.86, 111.23, 116.48, 120.30, 120.77, 121.89, 123.75, 123.79, 126.41, 128.16, 128.44, 128.72, 136.44, 139.53, 144.29, 167.92 (C[double bond, length as m-dash]O). Anal. calcd for C21H17NO3: C, 76.12; H, 5.17; N, 4.23%. Found: C, 76.08; H, 5.21; N, 4.17.
Synthesis of methyl 1-(benzyloxy)-6-fluoro-9H-carbazole-3-carboxylate (14). Following the same procedure adopted for the synthesis of 13, the cyclodehydrogenation of compound 12 in acetic acid gave the title compound 14 as a colorless solid. Yield: 0.09 g, 59%; m.p. 172–176 °C; IR (neat): 3325, 2939, 1687, 1608, 1582, 1480, 1455, 1433, 1407, 1325, 1300, 1275, 1249, 1167, 1095, 1017 cm−1; 1H-NMR (500 MHz, CDCl3): δ 3.97 (s, 3H, OCH3), 5.27 (s, 2H, OCH2Ph), 7.17 (td, J = 2.4, 9.1 Hz, 1H), 7.35–7.45 (m, 4H, Ar–H), 7.51 (d, J = 7.0 Hz, 2H, Ar–H), 7.69 (d, J = 1.3, 1H, Ar–H), 7.72 (dd, J = 8.2, 1.6 Hz, 1H, Ar–H), 8.42 (d, J = 1.2, 1H, Ar–H), 8.51 (br. s, 1H, NH); 13C-NMR (125.7 MHz, CDCl3): δ 52.11 (OCH3), 70.69 (OCH2Ph), 106.31, 106.50, 108.04, 111.81, 111.90, 114.23, 114.44, 116.58, 121.89, 123.39, 124.34, 128.16, 128.47, 128.73, 134.08, 135.78, 136.28, 144.36, 159.42 (d, J = 249.0 Hz, C-6), 167.76 (C[double bond, length as m-dash]O). Anal. calcd for C21H16FNO3: C, 72.20; H, 4.62; N, 4.01%. Found: C, 72.17; H, 4.65; N, 3.96.
Synthesis of methyl 1-hydroxy-9H-carbazole-3-carboxylate (15). To a suspension of 13 (0.48 g, 1.44 mmol) in a mixture of THF (20 mL) and ethanol (20 mL) was added palladium on activated carbon (0.05 g, 10% wet basis) and the reaction mixture was subjected to hydrogenation in a Parr apparatus at 50 psi for 5 h. The mixture was filtered through a pad of celite, and the filtrate was concentrated under vacuum and loaded on a silica column, eluting petroleum ether[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate (66[thin space (1/6-em)]:[thin space (1/6-em)]33) afforded 15 as a white solid. Yield: 0.32 g, 91%. The spectral data of 15 matched with those of earlier values.23
Synthesis of methyl 6-fluoro-1-hydroxy-9H-carbazole-3-carboxylate (16). Following the same procedure adopted for the synthesis of 15, the title compound 16 was obtained as a white solid from the O-debenzylation of 14. Yield: 0.2 g, 95%; m.p. 220–221; IR (neat): 3388, 3078, 2952, 1711, 1664, 1634, 1496, 1292, 1252, 1169 cm−1; 1H-NMR (500 MHz, DMSO-d6): δ 3.91 (s, 3H, OCH3), 7.31 (td, J = 1.6, 8.8 Hz, 1H, Ar–H), 7.52 (d, J = 1.3 Hz, 1H, Ar–H), 7.55 (dd, J = 4.2, 8.8 Hz, 1H, Ar–H), 8.10 (d, J = 7.9 Hz, 1H, Ar–H), 8.38 (d, J = 1.3 Hz, 1H, Ar–H), 10.35 (br. s, 1H, NH), 11.64 (s, 1H, OH); 13C-NMR (125.7 MHz, DMSO-d6): δ 51.75 (OCH3), 106.33, 110.29, 112.56, 112.63, 113.72, 113.92, 114.63, 120.58, 123.10, 124.34, 136.63, 142.99, 159.12 (d, J = 247.0 Hz, C-6), 166.98 (C[double bond, length as m-dash]O). Anal. calcd for C14H10FNO3: C, 64.86; H, 3.89; N, 5.40%. Found: C, 64.82; H, 3.94; N, 5.35.
Synthesis of methyl 1-hydroxy-2-(3-methylbut-2-en-1-yl)-9H-carbazole-3-carboxylate (19). To a solution of compound 15 (0.45 g, 1.87 mmol) and isobutyl 2-methylbut-3-en-2-yl carbonate (0.61 g, 2.76 mmol) in THF (12 mL) at room temperature was added tetrakis(triphenylphosphine)palladium (0.036 g, 0.03 mmol) and the mixture was stirred at room temperature for 6 h. The reaction mixture was diluted with ethyl acetate (20 mL) and the whole was washed with brine, dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography, eluting with petroleum ether[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate (80[thin space (1/6-em)]:[thin space (1/6-em)]20) to give O-allyl ether 17, which was used as is in the next reaction. In a microwave reaction vessel, a solution of 17 in DMF (2 mL) was bubble through nitrogen for 1 min and vessel was then placed inside CEM Discover S-Class microwave synthesizer where it was exposed to microwaves at 180 °C (260 W) for 2 h. After completion of the reaction and work up the residue was purified on silica gel column chromatography, eluting with hexanes[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate (66[thin space (1/6-em)]:[thin space (1/6-em)]33) to get the title compound 19 as a white crystalline solid. Yield: 0.47 g, 82%; m.p. 131–132 °C; IR (neat): 3482, 3313, 2928, 1701, 1646, 1608, 1490, 1443, 1347, 1288, 1253, 1226, 1160, 1039 cm−1; 1H-NMR (500 MHz, CDCl3): δ 1.68 (s, 3H, CH3), 1.83 (s, 3H, CH3), 3.92 (s, 3H, OCH3), 3.97 (d, J = 5.8 Hz, 2H, ArCH2–), 5.29 (m, 1H, ArCH2CH[double bond, length as m-dash]C(CH3)2), 5.66 (br. s, 1H, OH), 7.25 (m, 1H, Ar–H), 7.41–7.46 (m, 2H, Ar–H), 8.04 (d, J = 7.6 Hz, 1H, Ar–H), 8.37 (d, J = 1.2 Hz, 1H, Ar–H), 8.43 (br. s, 1H, NH); 13C-NMR (125.7 MHz, CDCl3): 18.10 (CH3), 25.75 (CH3), 25.96 (CH2), 51.95 (OCH3), 111.12, 115.36, 116.88, 119.96, 120.51, 121.76, 122.37, 122.51, 123.70, 126.15, 131.90, 132.24, 137.23, 139.82, 140.37, 168.95 (C[double bond, length as m-dash]O). Anal. calcd for C19H19NO3: C, 73.77; H, 6.19; N, 4.53%. Found: C, 73.72; H, 6.24; N, 4.48.
Synthesis of methyl 6-fluoro-1-hydroxy-2-(3-methylbut-2-en-1-yl)-9H-carbazole-3-carboxylate (20). Following the same procedure adopted for the synthesis of 19, O-allylation of 16 followed by Claisen rearrangement in DMF under microwave irradiation gave the title compound 20 a white solid. Yield: 0.35 g, 85%; m.p. 121–122 °C; IR (neat): 3486, 3383, 2922, 1708, 1661, 1609, 1494, 1453, 1433, 1347, 1288, 1253, 1220, 1166, 1031 cm−1; 1H-NMR (500 MHz, DMSO-d6): δ 1.69 (s, 3H, CH3), 1.81 (s, 3H, CH3), 3.86 (s, 3H, OCH3), 3.92 (d, J = 5.8 Hz, 2H, ArCH2–), 5.26 (m, 1H, ArCH2CH[double bond, length as m-dash]C(CH3)2), 7.23 (td, J = 2.1, 8.8 Hz, 1H, Ar–H), 7.53 (dd, J = 4.3, 8.5 Hz, 1H, Ar–H), 7.95 (dd, J = 2.1, 9.7 Hz, 1H, Ar–H), 8.22 (s, 1H, Ar–H), 9.20 (br. s, 1H, NH), 11.09 (s, 1H, OH); 13C-NMR (125.7 MHz, DMSO-d6): δ 18.12 (CH3), 25.77 (CH3), 25.95 (CH2), 51.97 (OCH3), 106.03 (d, J = 23.86 Hz), 112.53, 113.53 (d, J = 24.89 Hz), 114.36, 116.13, 120.83, 121.55, 123.76, 131.95, 134.08, 136.43, 137.61, 140.34, 159.32 (d, J = 245 Hz, C-4), 168.16 (C[double bond, length as m-dash]O). Anal. calcd for C19H18FNO3: C, 69.71; H, 5.54; N, 4.28%. Found: C, 69.65; H, 5.59; N, 4.22.
Synthesis of methyl 1-methoxy-2-(3-methylbut-2-en-1-yl)-9H-carbazole-3-carboxylate (21). Following the same procedure adopted for the synthesis of 7, the reaction of compound 19 with iodomethane gave the title compound 21 as colorless crystalline solid. Yield: 0.20 g, 71%; m.p. 129–133 °C; IR (neat): 3334, 2936, 1707, 1685, 1626, 1605, 1568, 1494, 1430, 1389, 1342, 1242, 1097 cm−1; 1H-NMR (500 MHz, CDCl3): δ 1.69 (s, 3H, CH3), 1.82 (s, 3H, CH3), 3.91–3.96 (m, 8H, 2 × OCH3, ArCH2–), 5.24 (m, 1H, ArCH2CH[double bond, length as m-dash]C(CH3)2), 7.25 (m, 1H, Ar–H), 7.42–7.45 (m, 2H, Ar–H), 8.07 (d, J = 7.9 Hz, 1H, Ar–H), 8.58 (br. s, 1H, NH), 8.46 (s, 1H, Ar–H); 13C-NMR (125.7 MHz, CDCl3): δ 18.10 (CH3), 25.74 (CH3), 25.96 (CH2), 51.96 (OCH3), 61.08 (OCH3), 111.12, 120.16, 120.20, 120.46, 122.37, 122.66, 123.91, 124.19, 126.28, 131.28, 133.21, 135.57, 139.95, 143.22, 168.80 (C[double bond, length as m-dash]O). Anal. calcd for C20H21NO3: C, 74.28; H, 6.55; N, 4.33%. Found: C, 74.23; H, 6.60; N, 4.27.
Synthesis of methyl 6-fluoro-1-methoxy-2-(3-methylbut-2-en-1-yl)-9H-carbazole-3-carboxylate (22). Following the same procedure adopted for the synthesis of 7, the reaction of compound 20 with iodomethane gave the title compound 22 as a white solid. Yield: 0.15 g, 84%; m.p. 115–116 °C; IR (neat): 3395, 2967, 1692, 1631, 1609, 1587, 1485, 1434, 1377, 1345, 1320, 1274, 1230, 1187, 1167, 1040 cm−1; 1H-NMR (500 MHz, CDCl3): δ 1.69 (s, 3H, CH3), 1.82 (s, 3H, CH3), 3.91–3.96 (m, 8H, 2 × OCH3, ArCH2–), 5.22 (m, 1H, ArCH2CH[double bond, length as m-dash]C(CH3)2), 7.17 (td, J = 2.4, 8.8 Hz, 1H, Ar–H), 7.37 (dd, J = 4.2, 8.8 Hz, 1H, Ar–H), 7.68 (dd, J = 2.4, 8.8 Hz, 1H, Ar–H), 8.25 (br. s, 1H, NH), 8.40 (s, 1H, Ar–H); 13C-NMR (125.7 MHz, CDCl3): δ 18.12 (CH3), 25.77 (CH3), 25.94 (CH2), 52.00 (OCH3), 61.17 (OCH3), 106.35 (d, J = 24.90), 111.66 (d, J = 9.34), 114.13 (d, J = 24.90), 120.33, 122.28, 122.68, 123.93, 124.61, 124.68, 131.52, 133.81, 136.07, 136.55, 143.29, 157.89 (d, J = 236.54, C-6), 168.47 (C[double bond, length as m-dash]O). Anal. calcd for C20H20FNO3: C, 70.37; H, 5.91; N, 4.10%. Found: C, 70.33; H, 5.95; N, 4.06.
Synthesis of 1-methoxy-2-(3-methylbut-2-en-1-yl)-9H-carbazole-3-carboxylic acid (23). To a solution of 21 (0.01 g, 0.30 mmol) in a mixture of MeOH (2 mL) and THF (1 mL) was added a solution of KOH (15 mL, 30% in H2O) and the mixture was heated overnight at 50 °C. The reaction was cooled to room temperature, acidified to pH 4 with 2 M HCl and then extracted with ethyl acetate (2 × 30 mL). The organic layer was dried over anhydrous Na2SO4 and evaporated under reduced pressure. The residue was passed through a pad of silica, eluting with hexanes[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate (50[thin space (1/6-em)]:[thin space (1/6-em)]50) to afford compound 23 as a white crystalline solid. Yield: 80%, m.p. 176–177 °C; IR (neat): 3337, 3062, 2925, 1675, 1610, 1448, 1406, 1278, 1236, 1031 cm−1; 1H-NMR (500 MHz, CD3OD): δ 1.57 (s, 3H, CH3), 1.72 (s, 3H, CH3), 3.83 (s, 3H, OCH3), 3.85 (d, J = 5.5 Hz, 1H, ArCH2–), 5.14 (m, 1H, ArCH2CH[double bond, length as m-dash]C(CH3)2), 7.08 (td, J = 1.1, 7.95 Hz, 1H, Ar–H), 7.28 (td, J = 1.2, 7.35 Hz, 1H, Ar–H), 7.39 (d, J = 7.9 Hz, 1H, Ar–H), 7.93 (d, J = 7.95 Hz, 1H, Ar–H), 8.37 (s, 1H, Ar–H); 13C-NMR (125.7 MHz, CD3OD): δ 18.20 (CH3), 25.94 (CH3), 26.65 (CH2), 61.35 (OCH3), 120.62, 120.95, 121.00, 123.13, 123.73, 124.79, 125.65, 127.08, 131.50, 133.87, 137.05, 142.10, 144.72, 172.09 (C[double bond, length as m-dash]O). Anal. calcd for C19H19NO3: C, 73.77; H, 6.19; N, 4.53%. Found: C, 73.72; H, 6.24; N, 4.48.
Synthesis of 6-fluoro-1-methoxy-2-(3-methylbut-2-en-1-yl)-9H-carbazole-3-carboxylic acid (24). Following the same procedure adopted for the synthesis of 23, the basic hydrolysis of 22 gave the title compound 24 as a white crystalline solid from. Yield: 0.084 g, 77%; m.p. 196–197 °C; IR (neat): 3455, 3040, 2913, 1664, 1634, 1612, 1588, 1569, 1489, 1443, 1376, 1342, 1317, 1277, 1243, 1192, 1170, 1098 cm−1; 1H-NMR (500 MHz, CD3OD): δ 1.65 (s, 3H, CH3), 1.79 (s, 3H, CH3), 3.91–3.96 (s, 5H, OCH3, ArCH2–), 5.22 (m, 1H, ArCH2CH[double bond, length as m-dash]C(CH3)2), 7.14 (td, J = 2.4, 8.8 Hz, 1H, Ar–H), 7.43 (dd, J = 4.3, 8.8 Hz, 1H, Ar–H), 7.70 (dd, J = 2.4, 8.8 Hz, 1H, Ar–H), 8.45 (s, 1H, Ar–H); 13C-NMR (125.7 MHz, CD3OD): δ 18.19 (CH3), 25.92 (CH3), 26.66 (CH2), 61.35 (OCH3), 106.53 (d, J = 23.86), 113.05 (d, J = 9.34), 114.64 (d, J = 25.93), 121.28, 123.29, 125.34, 125.42, 125.79, 131.63, 134.35, 138.10, 138.41, 144.79, 158.96 (d, J = 234.47, C-6), 171.92 (C[double bond, length as m-dash]O). Anal. calcd for C19H18FNO3: C, 69.71; H, 5.54; N, 4.28%. Found: C, 69.67; H, 5.58; N, 4.22.
Synthesis of 3-(2-hydroxypropan-2-yl)-5-methoxy-3,4-dihydropyrano[4,3-b]carbazol-1(6H)-one (1). To an ice-cold solution of 23 (0.025 g, 0.081 mmol) in anhydrous CH2Cl2 (5 mL) was added m-CPBA (0.021 g, 0.122 mmol) and the reaction was stirred for 2 h at room temperature. After the completion of reaction (TLC analysis) the solvent was evaporated under vacuum and residue was diluted with H2O (5 mL) and extracted with ethyl acetate (2 × 10 mL). The combined organic extracts were washed with saturated NaHCO3 solution (2 × 6 mL) followed by water (6 mL) and brine (6 mL). The organic phase was dried over Na2SO4 and evaporated under vacuum. The residue was purified by silica column, eluting with hexanes[thin space (1/6-em)]:[thin space (1/6-em)]ethyl acetate (50[thin space (1/6-em)]:[thin space (1/6-em)]50) to get the title compound 1 as a light brown solid. Yield: 0.02 g, 78%. All the spectral data of 1 matched with those of natural mafaicheenamine A.12 1H-NMR (500 MHz, acetone-d6): δ 1.37 (s, 3H, H-4′/H-5′), 1.38 (s, 3H, H-4′/H-5′), 3.01 (dd, J = 12.5, 16.4 Hz, 1H, H-1′b), 3.47 (dd, J = 2.5, 16.4 Hz, 1H, H-1′a), 3.98 (s, 3H, OCH3), 4.30 (dd, J = 2.5, 12.6 Hz, 1H, H-2′), 7.25 (ddd, J = 1.3, 7.4, 8.1 Hz, 1H, H-6), 7.47 (ddd, J = 1.2, 7.3, 8.1 Hz, 1H, H-7), 7.56 (d, J = 8.1 Hz, 1H, H-8), 8.24 (d, J = 8.1 Hz, 1H, H-5), 8.60 (s, 1H, H-4), 10.95 (br. s, 1H, NH); 13C-NMR (125.7 MHz, acetone-d6): δ 23.30 (C-1′), 25.29 (C-5′), 26.86 (C-4′), 61.39 (OCH3), 71.28 (C-3′), 85.21 (C-2′), 112.62 (C-8), 118.04 (C-3), 119.92 (C-4), 121.09 (C-6), 121.52 (C-5), 124.46 (C-4a), 124.93 (C-4b), 127.59 (C-7), 129.69 (C-2), 137.50 (C-9a), 141.68 (C-8a), 142.17 (C-1), 166.49 (C-10).
Natural mafaicheenamine A12. 1H-NMR (400 MHz, acetone-d6): δ 1.37 (s, 6H, H-4′, H-5′), 3.02 (dd, J = 12.4, 16.4 Hz, 1H, H-1′b), 3.47 (dd, J = 2.4, 16.4 Hz, 1H, H-1′a), 3.99 (s, 3H, OCH3), 4.29 (dd, J = 2.4, 12.4 Hz, 1H, H-2′), 7.26 (ddd, J = 1.2, 7.2, 8.0 Hz, 1H, H-6), 7.46 (ddd, J = 1.2, 7.2, 8.0 Hz, 1H, H-7), 7.56 (d, J = 8.0 Hz, 1H, H-8), 8.23 (d, J = 8.0 Hz, 1H, H-5), 8.59 (s, 1H, H-4), 10.96 (br. s, 1H, NH); 13C-NMR (100 MHz, acetone-d6): δ 23.2 (C-1′), 25.3 (C-5′), 26.8 (C-4′), 61.3 (OCH3), 71.2 (C-3′), 85.1 (C-2′), 112.5 (C-8), 118.0 (C-3), 119.8 (C-4), 121.0 (C-6), 121.5 (C-5), 124.4 (C-4a), 124.9 (C-4b), 127.5 (C-7), 129.6 (C-2), 137.4 (C-9a), 141.6 (C-8a), 142.1 (C-1), 166.4 (C-10).
Synthesis of 9-fluoro-3-(2-hydroxypropan-2-yl)-5-methoxy-3,4-dihydropyrano[4,3-b]carbazol-1(6H)-one (2). Following the same procedure adopted for the synthesis of 1, the oxidative cyclization of 24 gave the title compound 2 as a white crystalline solid from. Yield: 0.036 g, 80%; m.p. 276–277 °C; IR (neat): 3506, 3218, 2989, 2971, 2933, 1691, 1634, 1612, 1584, 1506, 1482, 1385, 1362, 1323, 1293, 1265, 1240, 1216, 1166, 1121, 1080, 1045 cm−1; 1H-NMR (500 MHz, CD3OD): δ 1.38 (s, 3H, CH3), 1.39 (s, 3H, CH3), 3.00 (dd, J = 12.8, 16.4 Hz, 1H, H-1′b), 3.45 (dd, J = 16.4, 2.7 Hz, 1H, H-1′a), 3.98 (s, 3H, OCH3), 4.29 (dd, J = 2.7, 12.8 Hz, 1H, H-2′), 7.20 (dd, J = 6.4, 8.8 Hz, 1H, Ar–H), 7.48 (dd, J = 4.3, 8.8 Hz, 1H, Ar–H), 7.80 (dd, J = 2.4, 8.8 Hz, 1H, Ar–H), 8.55 (s, 1H, Ar–H); 13C-NMR (125.7 MHz, CD3OD): δ 21.96 (C-1′), 23.69 (CH3), 24.94 (CH3), 59.99 (OCH3), 70.41 (C-3′), 84.53 (C-2′), 105.55 (d, J = 24.90), 111.94 (d, J = 9.34), 113.98 (d, J = 25.98), 115.65, 119.32, 123.66, 123.86 (d, J = 9.33), 123.89, 128.53, 137.06, 137.84, 141.09, 157.79 (d, J = 235.50, C-6), 167.49 (C[double bond, length as m-dash]O). Anal. calcd for C19H18FNO4: C, 66.46; H, 5.28; N, 4.08%. Found: C, 66.40; H, 5.33; N, 4.03.

Conclusions

In conclusion, the first total synthesis of mafaicheenamine A, an antitumoral carbazole alkaloid having potent activity against breast cancer cell lines and moderate activities against oral cavity cancer and small lung cancer have been described. In addition, owing to high importance and utility of fluorine substituents in drug discovery, the synthesis of unnatural 6-fluoromafaicheenamine A has also been achieved. Moreover, our synthetic approach furnishes an expedient synthesis of clausine E, a key intermediate in the course of synthesis of mafaicheenamine A and 6-fluoromafaicheenamine A.

Acknowledgements

The research facilities and financial support by KFUPM Grant No.: SB131009 are gratefully acknowledged.

References

  1. A. D. Kinghorn, Drug discovery from natural products, in Foye's Principles of Medicinal Chemistry, ed. T. L. Lemke and D. A. Williams, 6th edn, Wolters Kluwer/Williams & Wilkins, Philadelphia, PA, USA, 2008, pp. 12–25 Search PubMed.
  2. D. J. Newman and G. M. Cragg, J. Nat. Prod., 2012, 75, 311–335 CrossRef CAS PubMed.
  3. (a) M. M. Rahman and A. I. Gray, Phytochemistry, 2005, 66, 1601–1606 CrossRef CAS PubMed; (b) W. Maneerat, W. Phakhodee, T. Ritthiwigrom, S. Cheenpracha, T. Promgool, K. Yossathera, S. Deachathai and S. Laphookhieo, Fitoterapia, 2012, 83, 1110–1114 CrossRef CAS PubMed; (c) T. Nagappan, P. Ramasamy, M. E. A. Wahid, T. C. Segaran and C. S. Vairappan, Molecules, 2011, 16, 9651–9664 CrossRef CAS PubMed.
  4. W. Maneerat, T. Ritthiwigrom, S. Cheenpracha, U. Prawat and S. Laphookhieo, Tetrahedron Lett., 2011, 52, 3303–3305 CrossRef CAS.
  5. N. Kongkathip and B. Kongkathip, Heterocycles, 2009, 79, 121–144 CrossRef CAS.
  6. S. Jagadeesh, S. Sinha, B. C. Pal, S. Bhattacharya and P. P. Banerjee, Biochem. Biophys. Res. Commun., 2007, 362, 212–217 CrossRef CAS PubMed.
  7. (a) W. Maneerat, T. Ritthiwigrom, S. Cheenpracha and S. Laphookhieo, Phytochem. Lett., 2012, 2012(5), 26–28 CrossRef; (b) T. Sripisut, S. Cheenpracha, T. Ritthiwigrom, U. Prawat and S. Laphookhieo, Rec. Nat. Prod., 2012, 6, 386–389 CAS.
  8. W. Maneerat, T. Ritthiwigrom, S. Cheenpracha, T. Promgool, K. Yossathera, S. Deachathai, W. Phakhodee and S. Laphookhieo, J. Nat. Prod., 2012, 75, 741–746 CrossRef CAS PubMed.
  9. J. Wang, Y. Zheng, T. Efferth, R. Wang, Y. Shen and X. Hao, Phytochemistry, 2005, 66, 697–701 CrossRef CAS PubMed.
  10. W. Maneerat, W. Phakhodee, S. Cheenpracha, T. Ritthiwigrom, S. Deachathai and S. Laphookhieo, Phytochemistry, 2013, 88, 74–78 CrossRef CAS PubMed.
  11. (a) H.-J. Knölker and K. R. Reddy, in The Alkaloids, ed. G. A. Cordell, Academic Press, Amsterdam, 2008, vol. 65, pp. 1–430 Search PubMed; (b) H.-J. Knölker, Chem. Lett., 2009, 38, 8–13 CrossRef.
  12. W. Maneerat and S. Laphookhieo, Heterocycles, 2010, 81, 1261–1268 CrossRef CAS.
  13. (a) H. J. Böhm, D. Banner, S. Bendels, M. Kansy, B. Kuhn, K. Müller, U. Obst-Sander and M. Stahl, ChemBioChem, 2004, 5, 637–643 CrossRef PubMed; (b) K. Müller, C. Faeh and F. Diederich, Science, 2007, 317, 1881–1886 CrossRef PubMed; (c) W. K. Hagmann, J. Med. Chem., 2008, 51, 4359–4369 CrossRef CAS PubMed; (d) K. L. Kirk, Curr. Top. Med. Chem., 2006, 6, 1447–1456 CrossRef CAS PubMed; (e) Y. Lou, Z. K. Sweeney, A. Kuglstatter, D. Davis, D. M. Goldstein, X. Han, J. Hong, B. Kocer, R. K. Kondru, R. Litman, J. McIntosh, K. Sarma, J. Suh, J. Taygerly and T. D. Owens, Bioorg. Med. Chem. Lett., 2015, 25, 367–371 CAS; (f) X. Deng, S. Kokkonda, F. El Mazouni, J. White, J. N. Burrows, W. Kaminsky, S. A. Charman, D. Matthews, P. K. Rathod and M. A. Phillips, J. Med. Chem., 2014, 57, 5381–5394 CrossRef CAS PubMed; (g) M. Boehringer, H. Fischer, M. Hennig, D. Hunziker, J. Huwyler, B. Kuhn, B. M. Loeffer, T. Luebbers, P. Mattei, R. Narquizian, E. Sebokova, U. Sprecher and H. P. Wessel, Bioorg. Med. Chem. Lett., 2010, 20, 1106–1108 CrossRef CAS PubMed.
  14. K. J. Eastman, E. P. Gillis and N. A. Meanwell, Tactical applications of fluorine in drug design and development, Fluorine in Heterocyclic Chemistry, Volume 1, 5-Membered Heterocycles and Macrocycles, ed. V. Nenajdenko, Springer International, Cham, Switzerland, 2014, pp. 1–54 Search PubMed.
  15. (a) B. K. Park, N. R. Kitteringham and P. M. O'Neill, Annu. Rev. Pharmacol. Toxicol., 2001, 41, 443–470 CrossRef CAS PubMed; (b) P. Gleeson, G. Bravi, S. Modi and D. Lowe, Bioorg. Med. Chem., 2009, 17, 5906–5919 CrossRef CAS PubMed; (c) A. G. Dossetter, Bioorg. Med. Chem., 2010, 18, 4405–4414 CrossRef CAS PubMed.
  16. J. A. Olsen, D. W. Banner, P. Seiler, B. Wagner, T. Tschopp, U. Obst-Sander, M. Kansy, K. Müller and F. Diederich, ChemBioChem, 2004, 5, 666–675 CrossRef CAS PubMed.
  17. (a) K. M. Arafeh and N. Ullah, Nat. Prod. Commun., 2009, 4, 925–926 CAS; (b) N. Ullah and K. M. Arafeh, Tetrahedron Lett., 2009, 50, 158–160 CrossRef CAS; (c) N. Ullah and S. A. Haladu, Nat. Prod. Commun., 2010, 5, 1077–1080 CAS; (d) N. Ullah, S. A. Haladu and B. A. Moosa, Tetrahedron Lett., 2011, 52, 212–214 CrossRef CAS.
  18. D. R. Vutukuri, P. Bharathi, Z. Yu, K. Rajasekaran, M.-H. Tran and S. Thayumanavan, J. Org. Chem., 2003, 68, 1146–1149 CrossRef CAS PubMed.
  19. A. B. Gamble, J. Garner, C. P. Gordon, S. M. J. O'Conner and P. A. Keller, Synth. Commun., 2007, 37, 2777–2786 CrossRef CAS.
  20. D. H. R. Barton, D. M. X. Donnelly, J.-P. Finet and P. J. Guiry, J. Chem. Soc., Perkin Trans. 1, 1991, 2095–2102 RSC.
  21. H.-J. Knolker and N. O'Sullivan, Tetrahedron, 1994, 50, 10893–10908 CrossRef.
  22. M. Schmidt and H.-J. Knolker, Synlett, 2009, 15, 2421–2424 Search PubMed.
  23. D. P. Kamat, S. B. Parsekar, V. P. Kamat and S. G. Tilve, Synthesis, 2014, 46, 2789–2793 CrossRef CAS.
  24. J. Roy, A. K. Jana and D. Mal, Tetrahedron, 2012, 68, 6099–6121 CrossRef CAS.
  25. A. K. Jana and D. Mal, Chem. Commun., 2010, 46, 4411–4413 RSC.

Footnote

Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ra03242g

This journal is © The Royal Society of Chemistry 2016
Click here to see how this site uses Cookies. View our privacy policy here.